Seasonal variability of exacerbations in patients with severe, uncontrolled asthma and clinical benefits of tezepelumab: Results from the PATHWAY phase 2b study

被引：0
|
作者：
Corren, J. [1 ]
Karpefors, M. [2 ]
Hellqvist, A. [2 ]
Parnes, J. R. [3 ]
机构：
[1] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[2] AstraZeneca, Gothenburg, Sweden
[3] Amgen Inc, Thousand Oaks, CA USA
来源：
ALLERGY | 2020年 / 75卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
0879
引用
收藏
页码：17 / 18
页数：2
相关论文
共 50 条
  • [1] Seasonal Variability of Exacerbations in Patients with Severe, Uncontrolled Asthma and Clinical Benefits of Tezepelumab: Results from the PATHWAY Phase 2b Study
    Corren, J.
    Karpefors, M.
    Hellqvist, A.
    Parnes, J. R.
    Colice, G.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [2] EFFECT OF TEZEPELUMAB ON EXACERBATIONS IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA, ACCORDING TO BASELINE BODY MASS INDEX: RESULTS FROM THE PHASE 2B PATHWAY STUDY
    Ambrose, C. S.
    Colice, G.
    Salapa, K.
    Parnes, J. R.
    Corren, J.
    [J]. THORAX, 2021, 76 : A83 - A83
  • [3] THE EFFECT OF TEZEPELUMAB ON EXACERBATIONS IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA ACCORDING TO BASELINE INHALED CORTICOSTEROID DOSE: RESULTS FROM THE PHASE 2B PATHWAY STUDY
    Corren, Jonathan
    Ambrose, Christopher
    Salapa, Kinga
    Parnes, Jane
    Colice, Gene
    [J]. CHEST, 2020, 158 (04) : 30A - 31A
  • [4] Effect of Tezepelumab on Exacerbations in Patients with Severe, Uncontrolled Asthma, According to Baseline Body Mass Index: Results from the Phase 2b PATHWAY Study
    Ambrose, Chris
    Colice, Gene
    Salapa, Kinga
    Parnes, Jane
    Corren, Jonathan
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (02) : AB25 - AB25
  • [5] Tezepelumab Treatment Effect on Annualized Rate of Exacerbations by Baseline Biomarkers in Uncontrolled Severe Asthma Patients: Phase 2b PATHWAY Study
    Corren, J.
    Garcia Gil, E.
    Parnes, J. R.
    Pham, T.
    Griffiths, J. M.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [6] Tezepelumab Reduces Exacerbations Across All Seasons in Patients with Severe, Uncontrolled Asthma: A Post Hoc Analysis of the PATHWAY Phase 2b Study
    Corren, Jonathan
    Karpefors, Martin
    Hellqvist, Asa
    Parnes, Jane R.
    Colice, Gene
    [J]. JOURNAL OF ASTHMA AND ALLERGY, 2021, 14 : 1 - 10
  • [7] Effects of Tezepelumab on Asthma Exacerbations and Type 2 Biomarkers in Patients with Severe, Uncontrolled Asthma with and Without Nasal Polyps: Results from a Post-Hoc Analysis of the Phase 2b PATHWAY Study
    Emson, C.
    Corren, J.
    Saapa, K.
    Hellqvist, A.
    Parnes, J. R.
    Colice, G.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [8] The Impact of Tezepelumab on Hospitalization and Emergency Department Visits in Patients with Severe Uncontrolled Asthma: Results from the Pathway Phase 2b Trial
    Corren, J.
    Chen, S.
    Callan, L.
    Garcia Gil, E.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [9] Seasonal variability of exacerbations of severe, uncontrolled eosinophilic asthma and clinical benefits of benralizumab
    DuBuske, Lawrence
    Newbold, Paul
    Wu, Yanping
    Trudo, Frank
    [J]. ALLERGY AND ASTHMA PROCEEDINGS, 2018, 39 (05) : 345 - 349
  • [10] Tezepelumab Reduces Multiple Key Inflammatory Biomarkers in Patients with Severe, Uncontrolled Asthma in the Phase 2b PATHWAY Study
    Pham, T.
    Ren, P.
    Parnes, J. R.
    Griffiths, J. M.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
12345